Intelligence Profile
Research Papers
The available research on IGF-1 LR3 consists entirely of preclinical studies, with no clinical trials identified in humans. The evidence base is limited and focuses primarily on animal models and laboratory investigations.
Animal Studies and Basic Research
Several studies have examined IGF-1 LR3 in sheep models. Research published in the American Journal of Physiology (2025, PMID: 39679943) found that IGF-1 LR3 did not promote growth in late-gestation growth-restricted fetal sheep, suggesting limited effectiveness in this specific developmental context. Another sheep study (Journal of Developmental Origins of Health and Disease, 2023, PMID: 37114757) investigated acute IGF-1 LR3 infusion effects on glucose-stimulated insulin secretion in fetal sheep, finding that observed effects did not persist when pancreatic islets were isolated and studied separately.
Neurological Applications
Two studies explored potential neurological applications. Research in male 5XFAD mice (Journal of Alzheimer's Disease, 2025, PMID: 39610283) showed that intranasal IGF-1 LR3 treatment promoted amyloid plaque remodeling in the cerebral cortex but failed to preserve cognitive function. A separate study (International Journal of Biological Macromolecules, 2025, PMID: 41015370) developed a nerve conduit incorporating controlled IGF-1 LR3 release for rat sciatic nerve regeneration, though specific efficacy outcomes were not detailed in the available information.
Manufacturing and Technical Studies
Research has also focused on production methods, including recombinant expression of IGF-1 LR3 in Pichia pastoris yeast systems (Applied Microbiology and Biotechnology, 2023, PMID: 37261455) and investigations of glycosylation requirements in Chinese hamster ovary cells for IGF-1 signaling (International Journal of Molecular Sciences, 2022, PMID: 36499281).
Surgical Applications
One study examined IGF-1 LR3 in muscle void fillers for treating volumetric muscle loss (Journal of Surgical Research, 2026, PMID: 41418663), though specific results were not provided in the available abstracts.
The research landscape shows IGF-1 LR3 being investigated across diverse applications, but the evidence remains entirely preclinical with mixed results and limited sample sizes typical of early-stage animal research. No human clinical trials have been conducted to establish safety or efficacy in people.